Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: Routine clinical pharmacokinetic data-Reference-Cited by-同舟云学术

Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: Routine clinical pharmacokinetic data

Published:1983-06 Issue:3 Volume:11 Page:303-319
ISSN:0090-466X
Container-title:Journal of Pharmacokinetics and Biopharmaceutics
language:en
Short-container-title:Journal of Pharmacokinetics and Biopharmaceutics

Author:

Sheiner Lewis B.,Beal Stuart L.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics

Link

http://link.springer.com/content/pdf/10.1007/BF01061870.pdf

Reference9 articles.

1. L. B. Sheiner and S. L. Beal. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model; routine clinical pharmacokinetic dataJ. Pharmacokin. Biopharm. 8:553–571 (1980).

2. L. B. Sheiner and S. L. Beal. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model; experimental pharmacokinetic data.J. Pharmacokin. Biopharm. 9:635–651 (1981).

3. S. L. Beal and L. B. Sheiner.NONMEM Users Guide, parts I & II. Technical Report, Division of Clinical Pharmacology, University of California, San Francisco (1980).

4. S. L. Beal. Asymptotic properties of optimization estimators for the independent not identically distributed case with application to extended least squares estimators. Technical Report, Division of Clinical Pharmacology, University of California, San Francisco (1982).

5. L. B. Sheiner, B. Rosenberg, and V. Marathe. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.J. Pharmacokin. Biopharm. 5:445–479 (1977).

Cited by 251 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The history and future of population pharmacokinetic analysis in drug development;Xenobiotica;2023-12-05

2. Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus;Clinical Pharmacokinetics;2023-08-03

3. Pharmacokinetic–Pharmacodynamic Modeling and Simulation in Clinical Practice and Studies;AAPS Introductions in the Pharmaceutical Sciences;2023

4. The Unphysical Hypothesis of Infinite Absorption Time;Revising Oral Pharmacokinetics, Bioavailability and Bioequivalence Based on the Finite Absorption Time Concept;2023

5. The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics;Journal of Pharmacokinetics and Pharmacodynamics;2022-11-11